Publicação
Consumption of potentially inappropriate drugs and medication reconciliation in the elderly
| Resumo: | In the elderly, the consumption of inappropriate drugs leads to the development of adverse events. Objectives: To know the magnitude of the problem and to understand whether drug reconciliation is a clinically and economically viable solution. Methodology: Systematic review, using the PICO method. The descriptors “Polypharmacy”, “Inappropriate Prescription”, “Drug Reconciliation”, “Drug utilization review“ and “Deprescribing“ were used. Results: The existence of inappropriate prescriptions is very prevalent. Drug reconciliation is effective in reducing it, but it is not proven to reduce adverse events. Lack of professional involvement, patient noncompliance and cost of implementation are barriers to consider. Conclusions: Drug reconciliation programs need to be improved to be clinically and economically sustainable. |
|---|---|
| Autores principais: | Almeida, Armando Manuel Gonçalves de |
| Outros Autores: | Santos, Sandra Mónica Silva; Santos, Miguel |
| Assunto: | Idoso Prescrição inapropriada Reconciliação de medicamentos Aged Inappropriate prescription Medication reconciliation |
| Ano: | 2017 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Instituição associada: | Associação Católica dos Profissionais de Enfermagem e Saúde (ACPES) |
| Idioma: | português |
| Origem: | Servir |
| Resumo: | In the elderly, the consumption of inappropriate drugs leads to the development of adverse events. Objectives: To know the magnitude of the problem and to understand whether drug reconciliation is a clinically and economically viable solution. Methodology: Systematic review, using the PICO method. The descriptors “Polypharmacy”, “Inappropriate Prescription”, “Drug Reconciliation”, “Drug utilization review“ and “Deprescribing“ were used. Results: The existence of inappropriate prescriptions is very prevalent. Drug reconciliation is effective in reducing it, but it is not proven to reduce adverse events. Lack of professional involvement, patient noncompliance and cost of implementation are barriers to consider. Conclusions: Drug reconciliation programs need to be improved to be clinically and economically sustainable. |
|---|